State of New Jersey Common Pension Fund D Invests $490,000 in Kiniksa Pharmaceuticals International, plc $KNSA

State of New Jersey Common Pension Fund D purchased a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 11,871 shares of the company’s stock, valued at approximately $490,000.

Several other large investors have also made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth $31,000. Quantbot Technologies LP acquired a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth $43,000. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at $44,000. Finally, TD Waterhouse Canada Inc. lifted its stake in shares of Kiniksa Pharmaceuticals International by 1,673.9% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 2,040 shares of the company’s stock valued at $79,000 after purchasing an additional 1,925 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $58.37 on Tuesday. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $24.85 and a fifty-two week high of $59.75. The firm has a fifty day moving average price of $47.67 and a two-hundred day moving average price of $43.86. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 64.86 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. During the same period last year, the business posted $0.11 earnings per share. The firm’s revenue was up 55.5% compared to the same quarter last year. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current year.

Analyst Ratings Changes

KNSA has been the topic of several analyst reports. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Friday, April 17th. Canaccord Genuity Group boosted their price target on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Finally, Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $60.86.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total value of $656,259.90. Following the sale, the director owned 12,546 shares in the company, valued at approximately $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 1,703 shares of the business’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total transaction of $79,513.07. Following the transaction, the chief operating officer directly owned 12,029 shares in the company, valued at $561,634.01. This trade represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 655,991 shares of company stock worth $34,167,123. Insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.